
BioSpectrum
the business of Bio & Health Sciences
ASIA EDITION

Solo-Dex and Polymedicure to bring opioid-free acute pain management to major Asian markets

August 14, 2025 | News

Polymed will manufacture Solo-Dex's flagship product, the Fascile Continuous Peripheral Nerve Block system



Solo-Dex, Inc., a US-based medical device innovator, and Polymedicure Ltd., India's leading manufacturer of high-quality medical devices, have announced a strategic manufacturing and supply partnership to bring Solo-Dex's patented, opioid-free regional anesthesia solutions to hospitals across India for the first time.

Under this agreement, Polymed will manufacture Solo-Dex's flagship product, the Fascile Continuous Peripheral Nerve Block system, in accordance with Solo-Dex's strict quality standards, for distribution across India and key global markets.

The product is already approved for clinical use in the United States and Europe and is now set to support India's expanding Enhanced Recovery After Surgery (ERAS) programmes and the growth of outpatient surgical care.

Solo-Dex's patented device installs in under two minutes and enables continuous, localised pain relief without opioids. Unlike conventional methods that may require IV sedation and can result in patient delirium, Solo-Dex minimises systemic drug exposure, and eliminates the need for oral opioids thereby improving patient safety, reducing recovery time, and decreasing demand on hospital resources.

The Solo-Dex and Polymed partnership is already engaging with leading hospital systems across India, with commercial availability expected to begin in Q4 2025.

In addition to serving India, the partnership aims to fulfill international demand across Asia, Africa, Latin America, and select European markets, with Solo-Dex overseeing global regulatory compliance and branding.